EUCTR2006-005556-32-IT进行中（未招募）不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential Hypertension - ND
MENARINI RICERCHE S.P.A.0 个研究点目标入组 1,400 人开始时间: 2007年9月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female Caucasian patients ≥ 18 years of age. A female of childbearing potential may be enrolled providing she:
- •- has a negative pregnancy test at screening/enrolment and randomisation, and
- •- is routinely using a highly effective method of birth control resulting in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, e.g. implants, injectables, combined oral contraceptives, hormone containing intra uterine devices (IUDs).
- •2.Patients with a diagnosis of essential hypertension, either treatment-naive or currently on anti-hypertensive medication in whom it is medically justifiable to withdraw treatment, and who are likely to meet the required BP inclusion criteria at randomisation (see inclusion criteria No. 3 below).
- •3.BP criteria at randomisation:
- •a)Mean sitting dBP ≥ 100 mmHg and ≤ 120 mmHg.
- •b)Mean sitting sBP ≥ 160 mmHg and ≤ 200 mmHg.
- •4.Patients who have freely given written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with mean sitting sBP values > 200 mmHg and/or dBP > 120 mmHg.
- •2. Pregnant or nursing women.
- •3. Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the tested medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological, oncological, neurological, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic patients.
- •4. Patients having a history of the following within the last six months: Myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident (stroke), or transient ischaemic attack.
- •5. Patients with clinically relevant significant abnormal laboratory values at screening/enrolment, including patients with:
- • aspartate aminotransferase/serum glutamic-oxaloacetic-transaminase (ASAT/SGOT) and alanine aminotransferase/serum glutamic ? pyruvate - transaminase (ALAT/SGPT) greater than twice the upper limit and/or gamma-glutamyltransferase (γ-GT) greater than three times the upper limit of laboratory reference range
- • potassium above the upper limit of laboratory reference range (unless high value is due to haemolytic blood sample).
- •6. Patients with secondary hypertension of any aetiology such as renal disease, pheochromocytoma, or Cushing?s syndrome.
- •7. Patients with contraindication to Hydrochlorothiazide (HCTZ) and/or OM.
- •8. Patients with electrocardiographic evidence of 2nd or 3rd degree atrioventricular (AV)-block, atrial fibrillation or other cardiac arrhythmia (requiring treatment), or bradycardia (< 50 beats/min as measured by mean radial heart rate).
- •9. Patients with severe heart failure (New York Heart Association stage III-IV), a narrowing of the aortic or bicuspid valve, an obstruction of cardiac outflow (obstructive, hypertrophic cardiomyopathy) or symptomatic coronary disease.
- •10. Patients with clinical evidence of a renal disease (including renovascular occlusive disease, nephrectomy and/or renal transplant, bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary kidney, or severe renal impairment as evidenced by creatinine clearance (CLCR) < 30 mL/min).
- •11. Patients with uncorrected coarctation of aorta and higher grades of acquired aortic stenosis.
- •12. Patients with clinically relevant hepatic impairment.
- •13. Patients with biliary obstruction.
- •14. Poorly controlled diabetic patients, defined as Type 1 or Type 2 patients with a fasting glucose >12.21 mmol/L [>220 mg/dL].
- •15. Patients with a history of a wasting disease (e.g. cancer), autoimmune diseases, connective tissue diseases, major allergies, or angioneurotic oedema.
研究者
相似试验
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-DKMenarini Ricerche S.p.A.1,400
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-CZMenarini Ricerche S.p.A.1,400
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-DEMenarini Ricerche S.p.A.1,400
尚未招募
3 期
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-Interferon Alfa-2a With Ribavirin in Interferon (IFN) Naive Patients Geno2/3Chronic Hepatits COral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12607000092493Human Genome Sciences, Inc920
招募中
3 期
Phase 3 Study to Evaluate the Efficacy and Safety of Orally Administered BF2.649 in Japanese Patients with Narcolepsy, Consisting of a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study (Part 1) and Subsequent Open-label Extension Study (Part 2)arcolepsyJPRN-jRCT2031220432chimura Naohisa123